Diagnostics
Biotech and pharma companies strengthen their executive leadership and board positions.
Immigration has been a central concern of President Donald Trump. Since taking office, his administration has put forth a number of policies to restrict the number of immigrants allowed each year, as well as from what nations those immigrants can come.
Two months after taking over as interim chief executive officer of Bay Area-based uBiome, John Rakow is stepping down from the company that has been under scrutiny from the Federal Bureau of Investigation (FBI).
Draper, based in Cambridge, Massachusetts, signed a tissue model development deal with Bristol-Myers Squibb. The companies will collaborate on developing a unique liver tissue model to screen drugs for toxicity.
Biotech and pharma companies from across the globe share pipeline and business updates.
New Diagnostic Test, CERT, Improves Risk Prediction Over Standard Laboratory Tests
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
Todos Medical Ltd. announced that CEO Herman Weiss, MD, MBA, FACOG, provided a corporate update and roadmap at LD Micro International Annual Invitational in Los Angelos, California.
Minimally-invasive blood test could complement colonoscopy in high-risk LS patients who are non-compliant with colonoscopy screening recommendations or may develop precancerous lesions in the interval between colonoscopies
Proteomics International meeting with US tier 1 national diagnostic groups to expand global roll-out of PromarkerD including EU and Mexico
PRESS RELEASES